Daiichi Sankyo to close research subsidiary U3 Pharma
Posted: 1 December 2015 | Victoria White | No comments yet
U3 Pharma is a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer…
Daiichi Sankyo Company has announced its decision to close its research subsidiary, U3 Pharma GmbH.
U3 Pharma is a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer. The company was founded in 2001 by scientists of the Max-Planck Institute of Biochemistry and in 2008 became a member of the Daiichi Sankyo Group.
U3 Pharma to transfer its R&D tasks to the Biologics Function
Daiichi Sankyo has said it intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the company has said that it has reviewed its global R&D capacities and has decided to concentrate core research functions of Daiichi Sankyo Group in future.
U3 Pharma will transfer its current research and development tasks to the Biologics Function in Tokyo.
Daiichi Sankyo has said it will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.